secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001193125-26-130433
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Viridian Therapeutics announces positive phase 3 topline results for elegrobart in active thyroid eye disease
--------------------------------------------------------------------------------

- REVEAL-1 met primary endpoint with 54% proptosis responder rate for elegrobart Q4W vs 18% placebo at week 24 (p<0.0001).
- Elegrobart Q8W achieved 63% proptosis responder rate vs 18% placebo at week 24.
- Complete resolution of diplopia in 51% of Q4W patients vs 16% placebo at week 24.
- BLA submission for elegrobart anticipated in Q1 2027; REVEAL-2 top-line data expected Q2 2026.
- Company ended Q4 2025 with $875M cash; veligrotug PDUFA date June 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312526130433/0001193125-26-130433-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312526130433/d27955d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-130433

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer